Bio-Techne Corp (TECH)

Nov 9, 2026

Bio-Techne Corporation (TECH) reported strong first-quarter fiscal 2027 results, surpassing Zacks Consensus Estimates for both adjusted earnings per share and net sales. The company also announced that its shareholders have approved the merger agreement with Merck KGaA, an important step towards the completion of the $11.3 billion acquisition expected by late 2026 or early 2027. This merger aims to strengthen their global presence and service capabilities across the life sciences value chain.

Nov 3, 2026

Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.08 per share for the quarter ended September 30, 2026. The dividend is payable on November 23, 2026, to shareholders of record by November 13, 2026, provided its transaction with Merck KGaA has not closed by that date. The company, a global life sciences firm, stated that future cash dividends would be considered quarterly by its Board of Directors.

Oct 30, 2026

Bio-techne Corp (NASDAQ: TECH) shows neutral near and mid-term readings, potentially moderating a long-term positive bias, with a mid-channel oscillation pattern in play. The article details three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) and provides multi-timeframe signal analysis, including specific support and resistance levels. An exceptional 36.2:1 risk-reward setup targeting a 10.4% gain versus 0.3% risk is highlighted.